Molecular and Cellular Biochemistry

, Volume 389, Issue 1–2, pp 59–68 | Cite as

The potential of Cystatin C and small dense LDL as biomarkers of coronary artery disease risk in a young Indian population

  • Anjali Manocha
  • Flora Gupta
  • Rajneesh Jain
  • Seema Bhargava
  • Mamta Kankra
  • Sabari Das
  • L. M. Srivastava
Article

Abstract

Coronary artery disease (CAD) affects Indians 5–6 years earlier than in the west, is diffuse and malignant, and poses a heavy burden on India’s developing economy. Traditional risk factors have failed to explain this high incidence of premature CAD and hence this study investigated the association of two novel risk biomarkers, cystatin C and small dense LDL (sdLDL) with the presence and severity of CAD. Cystatin C and sdLDL were estimated in 204 CAD patients ≤45 years of age and compared with 161 age-matched healthy controls. The traditional lipid profile parameters, i.e., cholesterol, LDL, HDL, triglycerides, apolipoproteins A1 and B, and Lp(a) were also measured in both groups. Cystatin C was significantly raised and mean LDL particle size significantly reduced in CAD patients as compared to controls. 62.7 % of CAD patients showed pattern B while 37.3 % patients showed pattern A. Of the traditional lipid tests, only HDL and apolipoprotein A1 showed a significant decrease in the CAD group. sdLDL was significantly associated with the severity of CAD, while cystatin C was not. Both cystatin C and sdLDL emerged as independent risk factors, however, of the two, sdLDL was a more sensitive predictor of CAD events. Cystatin C and mean LDL particle size are significantly and independently associated with the presence of CAD events in patients ≤45 years with normal kidney function. Hence, these novel risk biomarkers can be useful tools in reducing the morbidity and mortality associated with CAD in the productive Indian workforce.

Keywords

Cystatin C Small dense LDL Early detection Coronary artery disease Risk factors 

Notes

Acknowledgments

This study was supported by a research grant from the Indian Council of Medical Research (ICMR), New Delhi, India. We also acknowledge, with thanks, the help provided in the statistical analysis by Ms. Parul Takkar Chugh, Statistician, Sir Ganga Ram Hospital, New Delhi, India.

References

  1. 1.
    Bahl VK, Prabhakaran D, Karthikeyan G (2001) Coronary artery disease in Indians. Indian Heart J 53(6):707–713PubMedGoogle Scholar
  2. 2.
    Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S (1996) Coronary artery disease & its risk factors in the first generation immigrant Asian Indians to the United States of America. Indian Heart J 48:343–352PubMedGoogle Scholar
  3. 3.
    Enas EA (1998) High rates of coronary artery disease in Asian Indians in the United States despite intensive modification of life style. What next. Curr Sci 74:1081–1086Google Scholar
  4. 4.
    Negus BH, Williard JE, Glamam DB, Landau C, Snyder RW 2nd, Hillis LD, Lange RA (1994) Coronary anatomy and prognosis of young asymptomatic survivors of myocardial infarction. Am J Med 96:354–358PubMedCrossRefGoogle Scholar
  5. 5.
    Mammi MV, Pavithran P, Rahman PA, Pisharody R, Sugathan K (1991) Acute MI in North Kerala. A 20 years hospital based study. Indian Heart J 43:93–96PubMedGoogle Scholar
  6. 6.
    Danarag TJ, Acker MS, Danaraj W, Ong W, Yam T (1959) Ethnic group differences in coronary heart disease in Singapore. An analysis of necropsy records. Am Heart J 58:516–526CrossRefGoogle Scholar
  7. 7.
    Wilkinson P, Sayer J, Laji K, Grundy C, Marchant B, Kopelman P, Timmis AD (1996) Comparison of case fatality in south Asians and white patients after acute myocardial infarction. Br Med J 312:1330–1333CrossRefGoogle Scholar
  8. 8.
    Bhatia ML (1995) Prevalence of coronary artery disease in India. A contemporary view. Indian Heart J 47:339–342PubMedGoogle Scholar
  9. 9.
    David MM, Lorraine GO, Adam K, Janet KS, Gregory LK, Tomas B, Marian R (2007) Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 56:2774–2779CrossRefGoogle Scholar
  10. 10.
    Sarnak MJ, Levey AS, Schoolwerth A, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 108:2154–2169PubMedCrossRefGoogle Scholar
  11. 11.
    Fried LF, Schlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB (2003) Renal insufficiency as a predictor of cardiovascular outcome and mortality in elderly individuals. J Am Coll Cardiol 41:1364–1372PubMedCrossRefGoogle Scholar
  12. 12.
    Koenig W, Twardella D, Brenner H, Rothenbacher D (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular event: more than simply a marker of glomerular filtration rate. Clin Chem 51(2):321–327PubMedCrossRefGoogle Scholar
  13. 13.
    Shemesh O, Golbetz H, Kriss Myers BD (1985) Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28:830–838PubMedCrossRefGoogle Scholar
  14. 14.
    Laterza OF, Price CP, Scott MG (2002) Cystatin C: an unproved estimator of glomerular filtration rate? Clin Chem 48:699–707PubMedGoogle Scholar
  15. 15.
    Dharnidharka VR, Kwon C, Stevens G (2002) Cystatin C is superior to serum creatinine as a marker of kidney function: a meta analysis. Am J Kidney Dis 40:221–226PubMedCrossRefGoogle Scholar
  16. 16.
    Buysschaert M, Joudi I, Wallemacq P, Hermans MP (2003) Performance of serum cystatin-C versus serum creatinine in subjects with type I diabetes. Diabetes Care 26:1320PubMedCrossRefGoogle Scholar
  17. 17.
    Muntner P, Mann D, Winston J, Bansilal S, Farkouh ME (2008) Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic heart disease. Am J Cardiol 102:54–57PubMedCrossRefGoogle Scholar
  18. 18.
    Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P (2006) Plasma cystatin-C and development of coronary heart disease: the PRIME study. Atherosclerosis 185:375–380PubMedCrossRefGoogle Scholar
  19. 19.
    Shlipak MG, Katz R, Sarnak KJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS (2006) Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145:237–246PubMedCrossRefGoogle Scholar
  20. 20.
    Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly person. N Eng J Med 352:2049–2060CrossRefGoogle Scholar
  21. 21.
    Finney H, Newman J, Gruber W, Merle P, Price CP (1997) Initial evaluation of cystatin-C measurement by particle-enhanced immunonephelometry on the Behring nephelometer system (BNA, BN II). Clin Chem 43:1016–1022PubMedGoogle Scholar
  22. 22.
    Lui J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP (2004) Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24:1359–1366CrossRefGoogle Scholar
  23. 23.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of deaths, cardiovascular events, and hospitalization. N Eng J Med 351:1296–1305CrossRefGoogle Scholar
  24. 24.
    Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, Geshi E, Katagiri T (2002) Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J 144(6):1026–1035PubMedCrossRefGoogle Scholar
  25. 25.
    Marcovina SM, Kosehinsky ML (1998) Lp(a) as a risk factor for coronary artery disease. Am J Cardiol 82:57–62CrossRefGoogle Scholar
  26. 26.
    Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952–957PubMedCrossRefGoogle Scholar
  27. 27.
    Sung WK, Se-Jung Y, Tae SK, Kwon HM, Kim JH, Rhee J, Lee SJ, Park JK, Lim JY, Yoon YW, Hong BK (2006) Significance of small dense low-density lipoprotein as a risk factor for coronary artery disease and acute coronary syndrome. Yonsei Med J 47(3):405–414CrossRefGoogle Scholar
  28. 28.
    Koba S, Hirano T, Yoshino G, Sakai K, Sakaue T, Adachi M, Katagiri T (2002) Remarkably high prevalence of small dense low-density lipoprotein particles in Japanese men with coronary heart disease, irrespective of the presence of diabetes. Atherosclerosis 160(1):249–256PubMedCrossRefGoogle Scholar
  29. 29.
    Miyao Y, Kugiyama K, Kawano H, Motoyama T, Ogawa H, Yoshimura M, Sakamoto T, Yasue H (2000) Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 36:432–437PubMedCrossRefGoogle Scholar
  30. 30.
    Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Chronic Kidney Disease Epidemiology Collaboration using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247–254PubMedCrossRefGoogle Scholar
  31. 31.
    Bengtsson E, To F, Grubb A, Hakansson K, Wittgren L, Nilsson J, Jovinge S (2005) Absence of the protease inhibitor cystatin C in inflammatory cells results in large plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180:43–45CrossRefGoogle Scholar
  32. 32.
    Singh D, Whooley MA, Lx JH, Ali S, Shilpak MG (2007) Association of cystatin C and estimated GFR with inflammatory biomarkers: the Heart and Soul Study. Nephrol Dial Transpl 22:1087–1092CrossRefGoogle Scholar
  33. 33.
    Quing X, Furong W, Yunxia L, Jian Z, Xuping W, Ling G (2012) Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol 11:108–117CrossRefGoogle Scholar
  34. 34.
    Wang J, Sim AS, Wang XL, Salonikas C, Moriatis M, Naidoo D, Wilcken DE (2008) Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis 197:853–859PubMedCrossRefGoogle Scholar
  35. 35.
    Erriksson P, Jones KG, Brown LC, Greenhalgh RM, Hamsten A, Powell JT (2004) Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg 91:86–89CrossRefGoogle Scholar
  36. 36.
    Taglieri N, Fernandez-Berges DJ, Koenig W, Fernandez JMC, Consuegra-Sanchez L, Robles NR, Sanchez PL et al (2010) Plasma cystatin C for prediction of 1-year cardiac events in mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 209(1):300–305PubMedCrossRefGoogle Scholar
  37. 37.
    Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ (2004) Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 15:1307–1315PubMedCrossRefGoogle Scholar
  38. 38.
    Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629–636PubMedCrossRefGoogle Scholar
  39. 39.
    Koc M, Batur MK, Karaarslan O, Abali G (2010) Clinical utility of serum cystatin C in predicting coronary artery disease. Cardiol J 17(4):374–380PubMedGoogle Scholar
  40. 40.
    Sekizuka S, Yoshihiro JA, Kensuke K, Masahiro Y, Haruki M (2009) Cystatin C: a better marker to detect coronary artery sclerosis. J Cardiol 54:359–367PubMedCrossRefGoogle Scholar
  41. 41.
    Hirayama S, Miida T (2012) Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 414:215–224PubMedCrossRefGoogle Scholar
  42. 42.
    Lamarche B, Lemieux I, Despres JP (1999) The small, dense LDL phenotype and the risk of coronary artery disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25:199–211PubMedGoogle Scholar
  43. 43.
    Gardner CD, Fortmann SP, Krauss RM (1996) Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 276:875–881CrossRefGoogle Scholar
  44. 44.
    St-Pierre AC, Cantin B, Dabenais GR, Mauriege P, Benard PM, Despres JP, Lamarche B (2005) Low-density lipoprotein subfractions and the risk of ischemic heart disease in men: 13 year follow up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 25:553–559PubMedCrossRefGoogle Scholar
  45. 45.
    Rizzo M, Berneis K (2006) Low-density lipoprotein size and cardiovascular risk assessment. Q J Med 99:1–14CrossRefGoogle Scholar
  46. 46.
    Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepard J (1994) Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241–253PubMedCrossRefGoogle Scholar
  47. 47.
    Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, Ferrante G, Lenone AM, Porto I, Burzotta F, Brugaletta S, Biasucci LM, Crea F (2008) Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis 197:853–859CrossRefGoogle Scholar
  48. 48.
    Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y, Ban Y, Iso Y, Suzuki H, Katagiri T (2006) Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis 189:206–214PubMedCrossRefGoogle Scholar
  49. 49.
    Moon JY, Kwon HM, Kwon SW, Yoon SJ, Kim JS, Lee SJ, Park JK, Rhee JH, Yoon YW, Hong BK, Rim SJ, Kim HS (2007) Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 108:282–289PubMedCrossRefGoogle Scholar
  50. 50.
    Goel PK, Bharti BB, Pandey CM, Singh V, Tiwari S, Kapoor A (2003) A tertiary care hospital based study of conventional risk factors including lipid profile in proven coronary artery disease. Indian Heart J 55:234–240PubMedGoogle Scholar
  51. 51.
    Mohan V, Deepa R, Rani SS, Premlatha G, Chennai Urban Population Study (CUPS No) (2001) Prevalence of coronary artery disease and its relationship to lipid in a selected population in south India. J Am Coll Cardiol 38:682–687PubMedCrossRefGoogle Scholar
  52. 52.
    Ramachandaran A, Snehlata C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasanna Kumar KM, Nair JD, Diabetes Epidemiology Study Group in India (DESI) (2001) High levels of diabetes and impaired glucose tolerance in India. National Urban Diabetes Survey. Diabetologia 44:1094–1101CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Anjali Manocha
    • 1
  • Flora Gupta
    • 1
  • Rajneesh Jain
    • 2
  • Seema Bhargava
    • 1
  • Mamta Kankra
    • 1
  • Sabari Das
    • 1
  • L. M. Srivastava
    • 1
  1. 1.Department of BiochemistrySir Ganga Ram HospitalNew DelhiIndia
  2. 2.Department of CardiologySir Ganga Ram HospitalNew DelhiIndia

Personalised recommendations